Genmab up after Darzalex meets in Phase III for first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) gained DKK147 (11%) to DKK1,448 in Copenhagen on Thursday after it said Darzalex daratumumab met the primary endpoint in the Phase III ALCYONE trial as first-line treatment of multiple myeloma. The company added about DKK9 billion ($1.4 billion) in market cap.

A pre-planned interim analysis of ALCYONE showed that Darzalex plus Velcade bortezomib, melphalan and prednisone (VMP) significantly improved progression-free survival (PFS) vs. VMP alone (HR=0.5, 95% CI: 0.38, 0.65, p<0.0001). Median PFS in the Darzalex arm has not been reached, while the estimated median PFS in the VMP arm was 18.1 months. Based on the interim results, an IDMC has recommended unblinding the data...